Jigar Mistry of Buoyant Capital discusses the Indian market's potential upswing, cautioning against oversimplification due to global factors like tariffs and recessionary pressures. He highlights the nuanced impacts of trade dynamics and suggests a calibrated approach. Mistry advises focusing on large-cap stocks and specific sectors like banking, financials, and healthcare, while remaining cautious about the MFI space.
Our recommendation is always the fact that you need to stay invested long-term in your SIPs and when your market corrections happen, it is the best time to buy more because you are actually accumulating additional units which is basically a sale in the market, so you are getting to buy at a cheaper cost.
Muthoot Finance shares plummeted after the Reserve Bank of India (RBI) announced forthcoming comprehensive regulations for gold-backed loans, triggering a selloff. The new rules include a uniform Loan-to-Value (LTV) cap of 75% and stricter monitoring of gold loans for income generation. Other lenders with gold loan exposure, like Manappuram Finance and IIFL Finance, also experienced declines following the announcement.
Axis MF's Shreyash Devalkar suggests largecaps are fairly priced, while mid and smallcaps, despite growth potential, need further valuation correction. He notes earning downgrades are following stock price falls, with FY26 downgrades largely priced in. Devalkar favors financial services and pharmaceuticals, reducing exposure to export-oriented and industrial names, emphasizing a stock-picker market driven by risk-reward frameworks.
A massive steel sculpture now stands at San Francisco's Embarcadero Plaza. Marco Cochrane created 'R-Evolution,' a 45-foot nude woman. The art piece was first displayed at Burning Man. It features internal lights and a breathing mechanism. The Sijbrandij Foundation sponsors the installation. It aims to promote gender equality and challenge perceptions. The sculpture will remain for at least six months.
Sandip Sabharwal discusses the impact of tariffs on global trade and the Indian economy, highlighting potential opportunities in sectors like auto, cement, and infrastructure. He believes the volatility in asset prices should peak soon, with supportive fiscal and monetary policies benefiting domestic-focused companies.
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.
